Dr. Reddy’s Laboratories Limited

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2024🗂️ Report periods on file: 2024, 2023-04 to 2024-03, 2022-04 to 2023-03, 2021-04 to 2022-03

In its 2024 reporting, Dr. Reddy’s Laboratories Limited disclosed greenhouse gas emissions of 304.2K tCO2e/year (Scope 1 & 2). By scope: Scope 1: 189.5K tCO2e/year; Scope 2: 114.7K tCO2e/year; Scope 3: 867.0K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
304.2K tCO2e/year (Scope 1 & 2)
2024
⚡
Renewable Energy
48%
of total energy
💧
Water Usage
1.9M m3/year
2024
♻️
Waste
78.5K tons/year
2024

📊 Emissions by Scope (2024)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).189.5K tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.114.7K tCO2e/year
Scope 3Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.).867.0K tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
2024304.2K tCO2e/year (Scope 1 & 2)
2023-04 to 2024-031.60 mn tCO2e
2022-04 to 2023-031.9M tCO2e/year (Scope 1 & 2)

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Water positive by 2025
  • 100% living wages for extended workforce by 2025

📅 Medium-term

  • 100% renewable power by 2030
  • Carbon neutral in direct operations by 2030
  • 12.5% reduction in Scope 3 emissions by 2030
  • At least 35% women in senior leadership by 2030
  • 3% of workforce to be Persons with Disability (PwD) by 2030

🔭 Long-term

  • Serve 1.5 bn+ patients by 2030
  • 25% of new launches to be first to market by 2027
  • 3 innovative solutions annually to improve treatment from 2027
  • Gender parity by 2035

🌱 ESG Focus Areas

EnvironmentalSocialGovernance

⚠️ Challenges & Risks +

  • Regulatory compliance
  • Pharmacovigilance (PV)
  • Water Management
  • Waste Management
  • Energy and emissions management
  • Talent attraction and retention
  • Combating counterfeit medicines
  • Business continuity
  • Business ethics/bribery and corruption
  • Geopolitical risk

📋 Report Information

Reporting Period: 2024
Frameworks: GRI Standards 2021, UN SDGs, NGRBC
Assurance: DNV Business Assurance India Private Limited